希瑪醫療控股有限公司（股份代號：03309）於2025年12月29日公告，基於翌日披露報表顯示，公司於同日於香港聯交所回購股份，涉及數量共計340,000股。
\n\n公告披露，回購價格介乎每股1.69港元至1.74港元，合共付出約580,720港元。本次回購股份佔此前已發行股本（不包括庫存股份）約0.028%。回購前，公司的已發行股份（不包括庫存股份）為1,213,120,870股，庫存股份為19,222,000股；完成後，已發行股份（不包括庫存股份）降至1,212,780,870股，庫存股份上升至19,562,000股。
\n\n公告顯示，上述回購根據2025年5月19日獲股東通過的購回授權進行，授權總數為125,556,087股，截至目前已回購340,000股，佔該授權通過當日已發行股份約0.0271%。公司同時確認已遵守香港聯交所主板上市規則的相關規定。本次公告由公司秘書陳華平簽署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.